RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Fourth Hospital of Hebei Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07823270, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma.

    Inclusion criterion 2

  3. Normal thyroid function, defined as TSH within the normal range. If baseline TSH is outside the normal range, participants with total T3 (or FT3) and FT4 within the normal range are also eligible.

    Inclusion criterion 12

  4. ECOG performance status of 0 or 1 within 7 days before dosing.

    Inclusion criterion 6

  5. Hematology: NEUT# >=1.5x10\^9/L; PLT >=100x10\^9/L; hemoglobin >=90 g/L.

    Inclusion criterion 8

    Hepatic: AST and ALT <=2.5xULN (<=5xULN for participants with baseline liver metastases); albumin >=30 g/L; total bilirubin <=1.5xULN.

    Inclusion criterion 9

    Renal: creatinine clearance >=60 mL/min (Cockcroft-Gault formula).

    Inclusion criterion 10

  6. At least one measurable lesion per RECIST v1.1.

    Inclusion criterion 5

  7. History of other malignancies within 5 years (except cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma in situ of the cervix).

    Exclusion criterion 2

    Active hepatitis B (HBsAg positive with HBV-DNA >=500 IU/mL or above the lower limit of detection, whichever is higher) or hepatitis C (HCV antibody positive with HCV-RNA above the lower limit of detection). Participants who are HBsAg positive are required to receive anti-hepatitis B viral therapy during the study.

    Exclusion criterion 18

    Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.

    Exclusion criterion 19

  8. Women of childbearing potential and men with partners of childbearing potential must agree to use effective medical contraception from informed consent until 6 months after the last dose.

    Inclusion criterion 15

    Pregnant or breastfeeding women.

    Exclusion criterion 25

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07823270, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age >=18 years at the time of informed consent, either sex.
  • Histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma.
  • Judged by imaging and esophagoscopy as resectable and requiring neoadjuvant therapy, with clinical stage cT1-2N+M0 or T3-4N0-3M0 (stage II-IVA).
  • No prior antitumor therapy for esophageal squamous cell carcinoma.
  • At least one measurable lesion per RECIST v1.1.
  • ECOG performance status of 0 or 1 within 7 days before dosing.
  • Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony-stimulating factor within 2 weeks before the first dose):
  • Hematology: NEUT# >=1.5x10\^9/L; PLT >=100x10\^9/L; hemoglobin >=90 g/L.
  • Hepatic: AST and ALT <=2.5xULN (<=5xULN for participants with baseline liver metastases); albumin >=30 g/L; total bilirubin <=1.5xULN.
  • Renal: creatinine clearance >=60 mL/min (Cockcroft-Gault formula).
  • Coagulation: INR, APTT, and PT <=1.5xULN.
  • Normal thyroid function, defined as TSH within the normal range. If baseline TSH is outside the normal range, participants with total T3 (or FT3) and FT4 within the normal range are also eligible.
  • Cardiac enzymes within the normal range (isolated laboratory abnormalities judged by the investigator as not clinically significant are allowed).
  • Left ventricular ejection fraction >=55%.
  • Women of childbearing potential and men with partners of childbearing potential must agree to use effective medical contraception from informed consent until 6 months after the last dose.
  • Participants voluntarily join the study, sign the informed consent form, and are able to comply with the scheduled visits and procedures.

Exclusion Criteria:

  • Any prior antitumor therapy for the currently diagnosed esophageal squamous cell carcinoma.
  • History of other malignancies within 5 years (except cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma in situ of the cervix).
  • Requirement for strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks before the first dose or during the study.
  • Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that interferes with or delays corneal healing.
  • Any of the following cardiovascular or cerebrovascular diseases or risk factors:
  • Myocardial infarction, unstable angina, acute or persistent myocardial ischemia, grade 3 or 4 heart failure (NYHA classification), symptomatic or poorly controlled severe arrhythmia, cerebrovascular accident, transient ischemic attack, or other severe cardiovascular or cerebrovascular diseases within 6 months before dosing.
  • History of myocarditis, primary cardiomyopathy, or specific cardiomyopathy.
  • Any deep vein thrombosis (participants stabilized with low molecular weight heparin or similar therapy for >=2 weeks may be allowed), peripheral arterial thromboembolic event, pulmonary embolism, or other severe thromboembolic events within 3 months before dosing.
  • Aortic aneurysm, aortic dissecting aneurysm, or other major vascular disease that may be life-threatening or requires surgery within 6 months before dosing.
  • Uncontrolled systemic disease as judged by the investigator:
  • Poorly controlled diabetes mellitus (two consecutive fasting glucose levels >=9 mmol/L).
  • Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg).
  • Symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  • History of steroid-requiring (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis; current ILD or non-infectious pneumonitis; or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging at screening.
  • Active autoimmune disease requiring systemic treatment within the past 2 years, including disease-modifying drugs, immunosuppressants, or systemic corticosteroids (>10 mg/day prednisone or equivalent). Hormone replacement therapy such as thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency is not considered systemic treatment. Participants receiving systemic corticosteroids >10 mg/day prednisone or other immunosuppressive drugs within 2 weeks before dosing.
  • Known active pulmonary tuberculosis. Participants with suspected active pulmonary tuberculosis must undergo clinical evaluation to exclude it.
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Active hepatitis B (HBsAg positive with HBV-DNA >=500 IU/mL or above the lower limit of detection, whichever is higher) or hepatitis C (HCV antibody positive with HCV-RNA above the lower limit of detection). Participants who are HBsAg positive are required to receive anti-hepatitis B viral therapy during the study.
  • Positive human immunodeficiency virus (HIV) test or history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  • Known hypersensitivity to the study drugs or any of their components, or a history of severe hypersensitivity reactions to other biologics.
  • Severe infection within 4 weeks before dosing, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective therapy within 2 weeks before dosing.
  • Receipt of non-specific immunomodulatory therapy (including but not limited to interferon, IL-2) or Chinese patent medicines approved for antitumor indications within 2 weeks before dosing.
  • Receipt of a live vaccine within 30 days before dosing, or planned receipt of a live vaccine during the study.
  • Rapid deterioration during screening before dosing, such as a marked change in performance status.
  • Pregnant or breastfeeding women.
  • Local or systemic diseases caused by non-malignant conditions, or diseases or symptoms secondary to the tumor, that may lead to high medical risk and/or uncertainty in survival evaluation, such as leukemoid reaction or cachexia.
  • Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, participant safety, or interpretation of study results, or any other condition that makes the participant unsuitable for this study.

Quoted from ClinicalTrials.gov, NCT07823270, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07823270, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07823270